PmpD Polypeptide Vaccine for Chlamydia Trachomatis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlling Chlamydia trachomatis infections lack an effective vaccine and therapeutic options, with existing measures failing to alter incidence or disease severity, posing a significant public health challenge due to the pathogen's prevalence and associated complications such as infectious blindness and sexually transmitted diseases.
Innovation Solution
Development of polypeptides and pharmaceutical compositions comprising immunogenic portions of Chlamydia antigens, specifically the PmpD protein, along with recombinant expression vectors and immunostimulants, to stimulate an immune response and provide prophylactic and therapeutic solutions, including vaccines and diagnostic kits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aggressive measures are taken to manage C. trachomatis infections, then disease control efforts are intensified, but incidence and disease severity remain unchanged
Solution Approach 1:
The patent applies preliminary action by developing and providing vaccine compositions before infection occurs or as preventive therapy. The vaccine compositions containing PmpD polypeptides are designed to induce protective immunity in advance, preventing the infection rather than treating it after establishment, thereby addressing the failure of reactive management approaches
Solution Approach 2:
The patent applies parameter changes by identifying and utilizing the PmpD polypeptide as a specific immunogenic antigen that elicits protective immune responses. This represents a change in the key parameter of antigen selection from conventional approaches to a specifically identified polymorphic membrane protein that demonstrates protective efficacy against multiple serovars
2Loss of time
If conventional vaccine development approaches are used, then extensive research time has been invested, but no practical vaccine against C. trachomatis diseases exists
Solution Approach 1:
The patent applies the extraction principle by isolating and utilizing the specific PmpD polypeptide from the complex C. trachomatis organism. Rather than attempting to develop vaccines from whole cell lysates or multiple antigens, the invention extracts the critical protective antigen (PmpD) and uses it as the basis for vaccine composition, simplifying the approach while maintaining efficacy
Solution Approach 2:
The patent applies universality by demonstrating that the PmpD polypeptide from C. trachomatis can elicit protective immune responses against multiple serovars and related Chlamydia species. This multi-protective capability allows a single vaccine composition to address diverse C. trachomatis strains, reducing the need for multiple serovar-specific vaccines
Data Source
AI summary
Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.